181 related articles for article (PubMed ID: 28840637)
1. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial.
Hwang YC; Yoon KH; Cha BS; Lee KW; Jang HC; Min KW; Chung CH; Lee MK
Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28840637
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Ando K; Ueshima K; Tanaka S; Kosugi S; Sato T; Matsuoka H; Nakao K; Fujita T
Int J Med Sci; 2013; 10(9):1209-16. PubMed ID: 23935398
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Matsuoka H; Ando K; Ueshima K; Babazono T; Kario K; Tanaka S; Nakao K; Fujita T;
Clin Exp Hypertens; 2011; 33(7):455-62. PubMed ID: 21649534
[TBL] [Abstract][Full Text] [Related]
4. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
[TBL] [Abstract][Full Text] [Related]
5. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
Miwa Y; Tsuchihashi T; Ohta Y; Tominaga M; Kawano Y; Sasaguri T; Ueno M; Matsuoka H
Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
[TBL] [Abstract][Full Text] [Related]
6. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
Morimoto S; Yano Y; Maki K; Iwasaka T
J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
[TBL] [Abstract][Full Text] [Related]
7. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
Katayama K; Nomura S; Ishikawa H; Murata T; Koyabu S; Nakano T
Kidney Int; 2006 Jul; 70(1):151-6. PubMed ID: 16710356
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
[TBL] [Abstract][Full Text] [Related]
9. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).
Uchida S; Takahashi M; Sugawara M; Saito T; Nakai K; Fujita M; Mochizuki K; Shin I; Morita T; Hikita T; Itakura H; Takahashi Y; Mizuno S; Ohno Y; Ito K; Ito T; Soma M
J Clin Hypertens (Greenwich); 2014 Oct; 16(10):746-53. PubMed ID: 25264215
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
[TBL] [Abstract][Full Text] [Related]
11. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
12. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study.
Martinez-Martin FJ; Saiz-Satjes M
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1347-55. PubMed ID: 19018688
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the anti-hypertensive effects of the L/N-type calcium channel antagonist cilnidipine, and the L-type calcium channel antagonist amlodipine in hypertensive patients with cerebrovascular disease.
Takei K; Araki N; Ohkubo T; Tamura N; Yamamoto T; Furuya D; Yanagisawa CT; Shimazu K
Intern Med; 2009; 48(16):1357-61. PubMed ID: 19687579
[TBL] [Abstract][Full Text] [Related]
14. A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers.
Konoshita T; Makino Y; Kimura T; Fujii M; Morikawa N; Wakahara S; Arakawa K; Inoki I; Nakamura H; Miyamori I;
Int J Cardiol; 2013 Jun; 166(2):448-52. PubMed ID: 22112682
[TBL] [Abstract][Full Text] [Related]
15. Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
; Uzu T; Sawaguchi M; Maegawa H; Kashiwagi A
Hypertens Res; 2008 Jun; 31(6):1171-6. PubMed ID: 18716365
[TBL] [Abstract][Full Text] [Related]
16. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Fukumoto S; Ishimura E; Motoyama K; Morioka T; Kimoto E; Wakikawa K; Shoji S; Koyama H; Shoji T; Emoto M; Nishizawa Y; Inaba M;
Diabetes Res Clin Pract; 2012 Jul; 97(1):91-8. PubMed ID: 22336632
[TBL] [Abstract][Full Text] [Related]
17. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.
Kojima S; Shida M; Yokoyama H
Hypertens Res; 2004 Jun; 27(6):379-85. PubMed ID: 15253102
[TBL] [Abstract][Full Text] [Related]
18. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension.
Sakata K; Shirotani M; Yoshida H; Nawada R; Obayashi K; Togi K; Miho N
Hypertension; 1999 Jun; 33(6):1447-52. PubMed ID: 10373231
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients.
Masaki M; Mano T; Eguchi A; Fujiwara S; Sugahara M; Hirotani S; Tsujino T; Komamura K; Koshiba M; Masuyama T
Heart Vessels; 2016 Nov; 31(11):1826-1833. PubMed ID: 26825736
[TBL] [Abstract][Full Text] [Related]
20. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
